There are currently no upcoming events.

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems Completes Patient Enrollment in Orbit II Coronary Trial 11/27/12
Study Evaluating Effectiveness of CSI’s Orbital Atherectomy Technology in Treating Calcified Coronary Arteries Nov. 27, 2012- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced it has completed enrollment in its ORBIT II clinical trial, enrolling 443 patients. ORBIT II is evaluating the safety and effectiveness of the company’s orbital atherectomy technology in treating severely calcified coronary arteries. It is estimated that moderate to severe arterial calcium is present in nearly 40 percent of those treated annually for coronary artery disease (CAD). ORBIT II is the first premarket approval (PMA) trial designed to study these difficult-to-treat patients. “Completing ORBIT II enrollment is a significant milestone in our efforts to secure a coronary indication to treat arterial calcium—a vastly underestimated problem in medicine today,” said David L. Martin , CSI president and chief executive officer. “At TCT this year, Dr. Philippe Genereux presented new data...
More >>
Cardiovascular Systems Featuring Training Lab at VEITH 2012 11/06/12
Attendees Will Have Hands-on Opportunity to Experience Effectiveness of Orbital Atherectomy at Treating Complex Calcium Nov. 6, 2012- Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), is offering 2012 VEITHsymposium™ attendees an opportunity to learn about the effectiveness of orbital atherectomy in treating peripheral arterial disease (PAD). Featuring live demos of the company’s revolutionary Orbital Atherectomy System, a hands-on training lab and the chance to engage with orbital atherectomy experts via CSIQ—the company’s official medical education program—attendees can experience firsthand what it takes to defeat complex arterial calcium. Arterial calcification is a common, underdiagnosed condition with complicating factors—including a higher frequency of dissections and perforations—that pose a challenge for physicians treating PAD. Calcified lesions are estimated to be present in approximately 65 percent of the people treated annually for PAD. CSIQ Training Lab: Friday, Nov. 16...
More >>